YERXA BENJAMIN R 4
4 · Opus Genetics, Inc. · Filed Apr 27, 2026
Research Summary
AI-generated summary of this filing
Opus Genetics (IRD) President Benjamin R. Yerxa Sells 7,470 Shares
What Happened
- Benjamin R. Yerxa, President and Director of Opus Genetics (IRD), sold 7,470 shares on 2026-04-23. The weighted average sale price was $5.24 per share, for total proceeds of approximately $39,121. This was a sale (disposition), not a purchase.
Key Details
- Transaction date: 2026-04-23; Form 4 filed: 2026-04-27 (timely).
- Price: weighted average $5.24; shares sold in multiple transactions at prices ranging $5.2314–$5.2413 (per footnote).
- Reason/footnote: Sold automatically to satisfy tax withholding obligations arising from vesting and settlement of a restricted stock unit (RSU) award — non‑discretionary (Footnote F1).
- Footnote F2: Reporting person can provide breakdown of how many shares were sold at each price within the stated range.
- Shares owned after the transaction: not provided in the excerpt of the filing.
Context
- Because the sale was an automatic withholding to cover taxes on RSU vesting (rather than a discretionary open‑market sell for investment reasons), it is generally considered routine and less indicative of the insider’s view on the company’s prospects.
Insider Transaction Report
Form 4
YERXA BENJAMIN R
DirectorPresident
Transactions
- Sale
Common Stock
[F1][F2]2026-04-23$5.24/sh−7,470$39,121→ 711,535 total
Footnotes (2)
- [F1]The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.
- [F2]The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $5.2314 to $5.2413, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Signature
/s/ Amy Rabourn, by Power of Attorney|2026-04-27